Talk:Saroglitazar
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Saroglitazar.
|
COI flag
editThe tone of this article, and the calling out of this particular drug well beyond what is supported by the extent of its use in general diabetes articles, seems to suggest that much of the editing is being performed by a company employee. The Adverse Effects section, for example, is no more than extensive reiteration of claims that the drug has no side effects, a claim which is hardly credible. It needs to be cleaned up to incorporate secondary sources and to provide a more objective view of the drug. Formerly 98 (talk) 15:09, 19 December 2014 (UTC)
Misleading claims and studies.
editI spent days researching this drug, and the studies that are uploaded seem to be ghostwritten by medical literature companies with absolutely no evidence. The studies have names of Indian doctors who are not qualified to conduct such studies. This company has been reprimanded by the US FDA for misleading claims[1], like the "First xxx drug approved globally" or the "First xxx drug approved by any FDA." One might think that the drug is approved globally or by the US FDA, but it's not. They mean it's the first drug of its kind to be approved in one country (India) around the globe and by the Indian FDA. Turk185 (talk) 16:03, 20 May 2023 (UTC)